溶栓治疗的实验室控制
THE LABORATORY CONTROL OF THROMBOLYTIC THERAPY.
作者信息
HAWKEY C, HOWELL M
出版信息
J Clin Pathol. 1964 May;17(3):287-91. doi: 10.1136/jcp.17.3.287.
Abstract
Methods are described by which thrombolytic therapy with local and systemic infusion of streptokinase can be initiated and controlled.
摘要
描述了启动和控制局部及全身输注链激酶进行溶栓治疗的方法。
相似文献
1
THE LABORATORY CONTROL OF THROMBOLYTIC THERAPY.溶栓治疗的实验室控制
J Clin Pathol. 1964 May;17(3):287-91. doi: 10.1136/jcp.17.3.287.
2
FIBRINOLYTIC THERAPY OF THROMBOEMBOLIC DISEASE.血栓栓塞性疾病的纤维蛋白溶解疗法。
Surg Gynecol Obstet. 1964 Sep;119:495-502.
3
[THE FIBRINOLYTIC THERAPY OF EXPERIMENTAL MASSIVE PULMONARY EMBOLISM IN RABBITS].[兔实验性大面积肺栓塞的纤维蛋白溶解疗法]
Minerva Cardioangiol. 1964 Jan;12:25-8.
4
THROMBOLYTIC THERAPY.溶栓治疗
J Clin Pathol. 1964 May;17(3):333-5. doi: 10.1136/jcp.17.3.333.
5
THROMBOLYTIC THERAPY.
Br Med Bull. 1964 Sep;20:228-32. doi: 10.1093/oxfordjournals.bmb.a070337.
6
CURRENT STATUS OF THROMBOLYTIC THERAPY.
Geriatrics. 1964 Sep;19:628-43.
7
Thrombolytic therapy.溶栓治疗。
Proc R Soc Med. 1963 May;56(5):414-8. doi: 10.1177/003591576305600536.
8
PRACTICAL METHOD FOR THROMBOLYTIC THERAPY WITH STREPTOKINASE. MAINTENANCE OF NEARLY COMPLETE PLASMINOGEN DEPLETION ASSOCIATED WITH HIGH CIRCULATING ACTIVATOR ACTIVITY.链激酶溶栓治疗的实用方法。维持与高循环激活剂活性相关的几乎完全的纤溶酶原消耗。
Br Med J. 1964 Mar 14;1(5384):675-6. doi: 10.1136/bmj.1.5384.675.
9
EXPERIENCE WITH STREPTOKINASE AS A THROMBOLYTIC AGENT.链激酶作为溶栓剂的应用经验。
Scand J Clin Lab Invest. 1964;16:SUPPL 79:7-14.
10
[THROMBOLYTIC THERAPY].[溶栓治疗]
Rass Fisiopatol Clin Ter. 1964 May-Jun;36:219-27.
引用本文的文献
1
ARTERIAL OCCLUSION TREATED WITH STREPTOKINASE. A REPORT OF TWO CASES.用链激酶治疗动脉闭塞。两例报告。
Postgrad Med J. 1965 Feb;41(472):96-100. doi: 10.1136/pgmj.41.472.96.
2
THE FIBRINOLYTIC MECHANISM IN HAEMOSTASIS: A REVIEW.止血中的纤维蛋白溶解机制：综述
J Clin Pathol. 1964 Sep;17(5):520-30. doi: 10.1136/jcp.17.5.520.
3
Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.链激酶治疗心肌梗死后的中和抗体：一个持续存在的谜题。
Br Heart J. 1995 Aug;74(2):122-3. doi: 10.1136/hrt.74.2.122.
本文引用的文献
1
Partial purification and properties of a proteolytic enzyme of human serum.人血清中一种蛋白水解酶的部分纯化及性质
J Biol Chem. 1949 Nov;181(1):431-48.
2
A new method for the determination of fibrinogen in small samples of plasma.一种测定少量血浆样本中纤维蛋白原的新方法。
J Lab Clin Med. 1951 Feb;37(2):316-20.
3
Activity of plasma labile factor in disease.疾病中血浆不稳定因子的活性
Lancet. 1951 Mar 17;1(6655):606-10. doi: 10.1016/s0140-6736(51)91115-4.
4
The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase.通过静脉输注链激酶对人体人工诱导的血管内血栓进行溶解。
J Clin Invest. 1959 Sep;38(9):1627-43. doi: 10.1172/JCI103941.
5
INTRAVENOUS STREPTOKINASE IN THE TREATMENT OF RETINAL VASCULAR OCCLUSION.静脉注射链激酶治疗视网膜血管阻塞
J Clin Pathol. 1964 May;17(3):363-4. doi: 10.1136/jcp.17.3.363.
6
A method for the comparison of the antiplasmin activity of two groups of blood sera.两组血清抗纤溶酶活性的比较方法。
J Clin Pathol. 1963 May;16(3):289-90. doi: 10.1136/jcp.16.3.289.
7
Determination of fibrinogen and fibrinogenolytic activity.纤维蛋白原及纤维蛋白原溶解活性的测定
Thromb Diath Haemorrh. 1962 Nov 15;8:297-310.
8
The specific assay of Prower-Stuart factor and factor VII.普罗氏-斯图尔特因子和因子 VII 的特异性测定。
Acta Haematol. 1961 Feb;25:105-20. doi: 10.1159/000206523.
9
The maintenance of a sustained thrombolytic state in man. I. Induction and effects.人体持续溶栓状态的维持。I. 诱导与效果。
J Clin Invest. 1959 Jul;38(7):1096-110. doi: 10.1172/JCI103886.
10
The mechanism of clot dissolution by plasmin.纤溶酶溶解血栓的机制。
J Clin Invest. 1959 Jul;38(7):1086-95. doi: 10.1172/JCI103885.
Zotero 插件